Xencor Inc
XE9
Company Profile
Business description
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
Contact
465 North Halstead Street
Suite 200
PasadenaCA91107
USAT: +1 626 305-5900
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
250
Stocks News & Analysis
stocks
10 best global blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalizations look undervalued today.
stocks
3 overvalued ASX shares going into earnings
Prices of these shares exceed our Fair Value Estimate by more than double.
stocks
The long-term case for compounders
Compounders tend to deliver steadier, more durable profit growth across full cycles, making them better suited for long-term investors.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,064.90 | 46.10 | -0.51% |
| CAC 40 | 8,126.53 | 55.17 | 0.68% |
| DAX 40 | 24,538.81 | 229.35 | 0.94% |
| Dow JONES (US) | 48,892.47 | 179.09 | -0.36% |
| FTSE 100 | 10,223.54 | 51.78 | 0.51% |
| HKSE | 26,748.36 | 638.75 | -2.33% |
| NASDAQ | 23,461.82 | 223.30 | -0.94% |
| Nikkei 225 | 52,928.59 | 394.26 | -0.74% |
| NZX 50 Index | 13,412.44 | 10.74 | -0.08% |
| S&P 500 | 6,939.03 | 29.98 | -0.43% |
| S&P/ASX 200 | 8,775.40 | 45.70 | -0.52% |
| SSE Composite Index | 4,065.31 | 52.64 | -1.28% |